As rapamycin activates Akt pathway by a negative feedback loop involving phosphorylation of insulin receptor substrate (IRS) by mTOR effector molecule S6 kinase [35,36], it was therefore not surprising that Rapamycin treatment induced Akt activation in some GBM patients in a Phase I clinical trial [9]. Here, IARS1 is linked to glioblastoma.